Trase Raises $107M Seed Round Led by ARCH Venture Partners to Build Agentic OS for Regulated Industries

What happened

Trase, founded by Grant Verstandig, announced a $107M seed round on June 25 led by ARCH Venture Partners with Red Cell Partners. Total funding now stands at $117.5M.

Context and impact

This is one of the largest seed rounds of 2026. ARCH Venture is traditionally a biotech/life-sciences investor, and its entry into agentic AI signals where the next enterprise-AI layer is forming — places where regulation has blocked full LLM rollout. The goal is an 'agentic OS' layer handling compliance, audit trails and task routing in healthcare and defense infrastructure.

Details

• Product: 'Trase Origin' — agentic OS for regulated workflows
• Lead investor: ARCH Venture Partners (well-known biotech backer)
• Pilot: Duke University Health System Cardiology — auto-routing 5,000+ monthly faxes
• Total funding: $117.5M
• Target markets: healthcare and government/defense workflows